CD44 and ovarian carcinoma: A route to inhibit angiogenesis is provided by HA-coated siRNA nanocarriers targeting CD44 on tumour endothelium [106]; this integrates vascular, stromal and immune targeting into multifunctional ovarian cancer nanomedicines.